WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Has files: NoSubject: search.filters.subject.polycystic ovary syndrome

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Circulating C-Terminal Propeptide of Type I Collagen (CICP) Levels in Women with Polycystic Ovary Syndrome
    (ORTADOGU AD PRES \& PUBL CO, 2012-01-01) Serteser, Mustafa; Fenkci, Ibrahim Veysel; Fenkci, Semin Melahat; Oztekin, Ozer
    Objective: Collagen type I is abundant in the outer layers of capsular stroma and theca externa in the ovary. C-terminal propeptide of Type I collagen (CICP) is the measurable form of type I procollagen in serum. Circulating CICP levels are indicative of collagen production. This study was designed to determine the serum levels of CICP and tissue inhibitor of metalloproteinase-1 (TIMP-1) levels in women with Polycystic Ovary Syndrome (PCOS). Material and Methods: This study included twenty-five women with PCOS in the study group and twenty healthy women in the control group. Serum lipid sub-fractions, fasting glucose and insulin, hormone (gonadotropins, androgens), CICP and TIMP-1 levels were measured. Homeostasis model assessment (HOMA-IR) was used to estimate insulin resistance. Results: Serum luteinizing hormone (LH) and fasting insulin levels, LH/follicule stimulating hormone (FSH) ratio, free androgen index (FAI) and HOMA-IR values were higher in patients with PCOS compared with healthy women. A significant increase in CICP level was observed in subjects with PCOS, and TIMP-1 level was found to be significantly decreased. HOMA-IR value was positively correlated with CICP level, but inversely with TIMP-1 level. The best cut-off values for CICP and TIMP-1 were >49.94 ng/mL (sensitivity 92.6\% and specificity 65\%) and <275.99ng/ml (sensitivity 92.6\% and specificity 40\%) respectively. Conclusion: Elevated circulating CICP levels may be associated with thickened tunics albuginea in women with PCOS. However, the exact role of CICP in the pathogenesis of the disease remains to be elucidated.
  • No Thumbnail Available
    Item
    Endotrophin as a novel marker in PCOS and its relation with other adipokines and metabolic parameters: a pilot study
    (SAGE PUBLICATIONS LTD, 2021-01-01) Guney, Gurhan; Taskin, Mine Islimye; Baykan, Ozgur; Adali, Ertan; Gul Tezcan, Selin; Sarikaya, Serkan; Kaya, Cihan; Tolu, Ezgi
    Background: Polycystic ovary syndrome is known to be the most common hormonal disorder in women of reproductive age. Current evidence shows that regulatory proteins secreted from the adipose tissue called adipokines may have a role in polycystic ovary syndrome. We planned to investigate the role of endotrophin that has never been researched in polycystic ovary syndrome before and its correlation with other metabolic parameters and adipokines such as adiponectin and ghrelin in patients with polycystic ovary syndrome. Methods: Forty-three women (n: 43) with polycystic ovary syndrome and 43 (n: 43) women as a control group were enrolled in this cross-sectional study. Serum levels of endotrophin, adiponectin, and ghrelin levels were measured with the enzyme-linked immunosorbent assay method. High-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol levels, luteinizing hormone/follicle-stimulating hormone ratio, total testosterone, and triglyceride levels were measured. Homeostasis model assessment for insulin resistance index, body mass index, Ferriman Gallwey Score, and waist-to-hip ratio were also evaluated. Results: Total testosterone, homeostasis model assessment for insulin resistance, C-reactive protein, luteinizing hormone/follicle-stimulating hormone ratio, and triglyceride levels were higher in patients with polycystic ovary syndrome (p < 0.01). No difference was detected between the groups in terms of body mass index, Ferriman Gallwey Score, waist-to-hip ratio, total cholesterol, low-density lipoprotein, and high-density lipoprotein levels (p > 0.05). We did not observe any significant difference in adiponectin and ghrelin levels between the groups (p > 0.05). Patients with polycystic ovary syndrome had significantly higher endotrophin levels (p < 0.01). According to our regression analyses {[}area under the curve: 0.973 (0.935-1.000), 95\% confidence interval, 95.2\% sensitivity, and 100\% specificity], it was shown that endotrophin greater than 92 ng/ml and homeostasis model assessment for insulin resistance greater than 2.5 might be good predictors for polycystic ovary syndrome diagnosis. Conclusion: We demonstrated that endotrophin level is higher in patients with polycystic ovary syndrome and may have predicted polycystic ovary syndrome with increased homeostasis model assessment for insulin resistance index. There was no significant difference in adiponectin and ghrelin levels in the polycystic ovary syndrome group. Endotrophin may have a role in polycystic ovary syndrome etiology rather than other adipokines.